Company intelligence / Profile preview

Tibetree

Ownership: Private
Development stage: Other

Overview

Tibetree is a clinical-stage biopharmaceutical company based in China that focuses on the discovery and development of innovative small molecule therapies for metabolic diseases. The company's primary research efforts are directed toward treating type 2 diabetes and related conditions such as obesity and nonalcoholic steatohepatitis (NASH). Its lead candidate, TT-063, is a potent and selective GPR40 agonist designed to improve glucose-dependent insulin secretion. Tibetree aims to address unmet medical needs in the metabolic space through a combination of internal R&D and strategic collaborations.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tibetree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tibetree.